Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: A nationwide cohort study

Clinical Infectious Diseases

Volumn 42, Issue 10, 2006, Pages 1481-1487

  Weis, Nina ^a   Lindhardt, Bjarne Ø ^b   Kronborg, Gitte ^a   Hansen, Ann Brit E ^b   Laursen, Alex L ^f   Christensen, Peer B ^c   Nielsen, Henrik ^d   Møller, Axel ^e   Sørensen, Henrik T ^f,g   Obel, Niels ^c  

^a HVIDOVRE HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e KOLDING HOSPITAL   (Denmark)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DENMARK; FEMALE; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; SERODIAGNOSIS; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DENMARK; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33646439994     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/503569     Document Type: Article

References (24)

1. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-7.
2. Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. The Italian Seroconversion Study. J Infect Dis 1995; 172:1503-8.
3. Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta VA (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999; 29:150-4.
4. De Luca A, Bugarini R, Lepri AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002; 162:2125-32.
5. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-5.
6. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288:199-206.
7. Rockstroh, JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992-1002.
8. Zylberberg H, Chaix M-L, Rabian C, et al. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. Clin Infect Dis 1998; 26:1104-6.
9. Chung RT, Ewans SR, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in coinfected subjects. AIDS 2002; 16:1915-23.
10. Martinez-Sierra C, Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003; 36:491-8.
11. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004; 18:2039-45.
12. Danmarks Statistik. Available at: http://www.statistikbanken.dk. Accessed 4 September 2005.
13. Statens Serum Institute. Available at: http://www.ssi.dk. Accessed 4 September 2005.
14. Lohse N, Hansen A-BE, Jensen-Fangel S, et al. Demographics of HIV-1 infection in Denmark: results from the Danish HIV Cohort Study. Scand J Infect Dis 2005; 37:338-43.
15. Jensen-Fangel S, Pedersen L, Pedersen C, et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1 infected patients. Clin Infect Dis 2002; 35:1541-8.
16. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989; 79:340-9.
17. Jensen-Fangel S, Pedersen L, Pedersen C, et al. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS 2004; 18:89-97.
18. Lewden C, Jacqmin-Gadda H, Vilde J-L, et al. An example of non-random missing data for hepatitis C virus status in a prognostic study among HIV-infected patients. HIV Clin Trials 2004; 5:224-31.
19. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection-host, viral, and environmental factors. JAMA 2000; 284:450-6.
20. Soriano-Sarabia N, Leal M, Delgado C, et al. Effect of hepatitis C virus coinfection on humoral immune alterations in naïve HIV-infected adults on HAART: a three-year follow-up study. J Clin Immunol 2005; 25:296-302.
21. Mocroft A, Phillips AN, Soriano V, et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005; 21:527-36.
22. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001;34:283-7.
23. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-13.
24. Mariné-Barjoan E, Saint-Paul M-C, Pradier C, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus coinfected patients. AIDS 2004; 18:2163-70.